Clinical Trial Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune – TGA Application to follow Aegros December 1, 2023
Investor Australia’s leading blood fractionator announces a trio of strategic advisor appointments as it lays the groundwork for an IPO Aegros November 23, 2023
HaemaFrac® Historic Joint Venture to Build 1m Litre HaemaFrac® Facility in Singapore & Cambodia Aegros August 7, 2023
Investor Aegros Appoints Father of India’s Blood Plasma Industry as Chief Executive Officer of Aegros Asia Aegros July 6, 2023
Industry Engagement Aegros to present findings at ISTH 2023 Pt 2 – Hyperimmune neutralisation against Covid-19 variants Aegros June 26, 2023
Culture Aegros Appoints Chief Medical Officer with large fractionator experience Aegros February 7, 2023
HaemaFrac® The Future of Fractionation: Aegros 1 Million Litre HaemaFrac®Facility Aegros November 29, 2022
HaemaFrac® Dream to Reality: Aegros’ plasma fractionation facility announced Aegros November 28, 2022
HaemaFrac® Queensland Government And Aegros Announce a One Million Litre Plasma Fractionation Plant in Springfield Aegros November 25, 2022
HaemaFrac® The University of Queensland and Aegros Celebrates Co-founder’s Professorship Aegros July 19, 2022
Covimmune™ Meta-analysis of Clinical Trial Studies Shows the Promise of Covimmune™ Aegros March 31, 2022
Fractionation AEGROS Awarded Collaborative Australian Research Council Linkage Project (ARCLP) Aegros February 25, 2019
